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1. Introduction 
Erectile dysfunction (ED) is the most common sexual problem in men [1]. ED is defined as a 
difficulty in initiating or maintaining penile erection adequate for sexual activity. ED has a 
weighty effect on intimate relationships, quality of life, and overall self-esteem for men. In 
addition, ED may also be an early indication of undetected cardiovascular disease [2]. One 
of the largest current studies of ED, the Massachusetts Male Aging Study, established that 
the prevalence of ED increases with age as it affects up to half of the male population 
between 40 and 70 years old [3]. Thus, as the world’s older population increases, it is 
estimated that the prevalence of ED will double from 152 million men in 1995 to 322 million 
men in 2025, indicating a dire need to reevaluate current ED therapeutic strategies [4]. In 
most documented cases, ED may also present with comorbidities of hypertension, diabetes 
mellitus, obesity, and atherosclerosis [3].  
During the 1980s, most of the pioneering research in ED was sparked by the introduction of 
intracavernosal vasoactive drugs, which were very effective as agents inducing penile 
rigidity [5]. It was not until the late 1990’s and early 2000’s that oral phosphodiesterase-5 
inhibitors were introduced, which were truly instrumental in revolutionizing the sexual 
medicine field [6]. Today, first-line therapy for the treatment of ED consists of orally as well 
as sublingually administered drugs, while intracavernosal injection (ICI), therapy, which 
involves direct injection of vasoactive agents into cavernosal tissue, is considered only as a 
second-line therapy. This chapter will discuss current perspectives on ED’s 
pharmacotherapy and present a more in-depth review on treatments for ED, based on the 
works from Andersson, K.E. [7] and Uckert, S. [8].  
2. First-line treatment: Oral pharmacotherapy 
2.1 PDE5 inhibitors  
The family of phosphodiesterases is comprised of 11 catalytic enzymes that regulate the 
second messenger activity in cells by cleavage of the phosphodiester bond of either cyclic 
adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP), or both [9] 
PDE5 is present in high concentrations in the smooth muscle of corpora cavernosa of the 
penis and in the smooth muscle of the pudendal arteries; therefore, phosphodiesterase 5 
www.intechopen.com
 
Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
146 
inhibitors (PDE5) are the major initial line of pharmacotherapy for erectile dysfunction (ED). 
PDEs are orally active agents that are taken, on demand, prior to sexual intercourse [9]. 
PDE5 was discovered by Corbin and colleagues [3, 4]. The PDE5 enzyme is a homo-dimer 
with two identical subunits, and each subunit is 100,000 kilo Daltons. Both subunits have a 
catalytic domain and a regulatory domain; however, it is the catalytic domain that is the 
main target for PDE5 inhibitors [9]. Nevertheless, it was the discovery of nitric oxide (NO) 
and cGMP as the major effectors in penile smooth muscle relaxation that led to the 
identification of PDE5 inhibitors that can further elevate intracellular levels of cGMP [10-11]. 
Most PDE5 inhibitors have a comparable structure to sildenafil; in addition, a part of the 
molecular structure of most PDE5 inhibitors bears resemblance to the cGMP structure. This 
is of significance since PDE5 inhibitors are competitive antagonists of both cGMP and  
PDE5 [7].  
The actions of PDE5 inhibitors are often described in terms of their selectivity when 
compared to other PDE inhibitors.  The selectivity of PDE5 inhibitors is a key factor since 
studies have shown that some PDE5 inhibitors may cross-react with PDE6, (predominant 
phosphodiesterase in the retina), causing visual disturbances; for example perception of 
bluish haze and increased light sensitivity, has occurred in some patients [12-13]. 
Additionally, some PDE5 inhibitors also cross-react with PDE11; PDE11 is mainly located in 
cardiac, testicular and pituitary tissues of the heart and testes; however, the consequences of 
this cross-reaction are unknown [7]. The normal pathway for penile erection is by sexual 
stimulation, which releases NO at nerve endings in the penis whereby increasing the blood 
supply to the penis. NO, the major vasodilatory agent causes this increase in blood by 
diffusing into vascular smooth muscle cells in both the penile corpus cavernosum and the 
pudendal arteries to cause stimulation of guanylyl cyclase (GS). Elevation of cGMP in these 
cells leads to the activation of cGMP-dependent protein kinase (PKG), a lowering of 
intracellular calcium, resulting in smooth muscle relaxation. PDE5 inhibitors act by 
selectively enhancing erectile function by penetrating into smooth muscle cells and 
inhibiting PDE5, resulting in decreased breakdown of cGMP, thus PDE5 inhibitors increase 
blood flow of the smooth muscle by increasing relaxation, allowing for an erection to occur 
[9, 14]. PDE5 inhibitors are degraded in the liver, since they are not metabolized by any 
other enzymes in the smooth muscle cells of the corpus cavernosum. So, PDE5 inhibitors 
must be transported to the liver in order to be degraded. This is important to note, as it 
determines the duration of action, because the disappearance of the inhibitor from the 
plasma may indicate, but does not always prove, its clearance from the cells in which its 
effects were produced [9].   
PDE5 inhibitors are the most widely used treatment for ED and their efficacy have been 
rigorously evaluated in numerous clinical trials [8]. Subjects receiving a PDE5 inhibitor 
report erections adequate for sexual intercourse [8, 15]. However, PDE5 inhibitors seem to 
be less effective in studies where male subjects have comorbid diseases such as diabetes [16]. 
Nevertheless, PDE5 inhibitors remain the primary line of oral treatment, and the most 
common reported side effects include headaches, dyspepsia, and nasal congestion [17-19]. In 
regard to cardiovascular (CV) safety, PDE5 inhibitors have proven to be safe in patients with 
CV disease; however, due to their mechanisms of action, PDE5 inhibitors are 
contraindicated in ED patients taking nitrates due to unpredictable hypotension [8]. On the 
other hand, it should be noted that the interaction between organic nitrates and PDE5 
inhibitors varies according to the PDE5 inhibitor and the nitrate used [7]. 
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2.1.1 Sildenafil 
Since the launch of sildenafil as an effective basis for the treatment of ED in 1998, similar 
agents have undergone clinical trials and have been subsequently introduced into clinical 
practice [14]. There is clear evidence that sildenafil is efficacious in the treatment of ED for 
the broad population of men [20]. As a result, sildenafil has proven effective in cases when 
ED has arisen as a consequence of comorbid diseases such as diabetes, depression, 
cardiovascular disease, hypertension and lower urinary tract infections [9].  
Sildenafil has shown efficacy when taken at doses of 25, 50, or 100 mg and has an onset of 
action usually within 25–60 minutes; however, absorption of the drug is slowed with food 
[9, 14, 21]. Minor side effects do occur with the use of sildenafil; the most reported side 
effects were headaches, flushing, indigestion, and visual changes [9, 19, 22]. Sildenafil will 
most likely continue to be the drug of choice for physicians, since there have not been any 
reports that have cast uncertainty on its safety for men with ED.  
2.1.2 Udenafil (DA-8159) 
Udenafil (DA-8159) is a PDE5 inhibitor; it is a long-acting drug with a half-time (t1/2) of 11–
13 hours, and it has a relatively fast absorption with the plasma concentration after ingestion 
reaching  its tmax, that is, its peak drug level, in 1–1.5 hours [4]. Phase II clinical trial data 
revealed that in men with mild-to-severe ED, udenafil produced a considerable 
improvement in erectile function after 12 weeks of treatment [8]. A phase III study in Korea 
evaluated the efficacy and safety of udenafil in ED patients. All responses to udenafil were 
significantly greater than the placebo (p < 0.0001) and patients receiving either udenafil 
doses of 100 mg or 200 mg were significantly (p < 0.0001) more satisfied with their sex life 
compared with men taking the placebo [4]. In animal studies, the administration of DA-8159 
(0.3 or 1 mg/kg) induced a dose-frequency dependent increase in intracavernosal pressure 
(ICP); chronic treatment with DA-8159 restored erectile responses induced by electric 
stimulation, improved endothelial function, and significantly decreased plasma levels of 
both endothelin, (a potent vasoconstrictor), and asymmetrical dimethyl arginine (ADMA), 
(an inhibitor of NO production) [8]. Udenafil has been reported to be a well tolerated, since 
most of the adverse side effects were flushing, upset stomach and headaches, which were 
generally mild to moderate [4, 8]. 
2.1.3 Avanafil 
Avanafil is a pyrimidine derivative synthesized to be a highly selective PDE5 inhibitor for 
the treatment of ED [9]. Studies have shown that up to 84% of avanafil doses resulted in 
sufficient erections for sexual activity, as compared to placebo [8]. In clinical trials, avanafil 
showed a higher selectivity, almost 120-fold, against PDE6 than both sildenafil and 
vardenafil [4]. Additionally, when compared with sildenafil, vardenafil, and tadalafil 
(described later), avanafil’s chemical structure is distinctive from the standard nucleic 
base/sugar/phosphate diester model; avanafil’s molecular structure is a nitrogen derivative 
of a pyrimidine carboxamide where the nitrogen atom of the amide substituent is bound to a 
pyrimidinylmethyl group [8]. As a result of its unique chemical structure, theoretically, 
avanafil can bind to the catalytic site of PDE5 regardless of the spatial orientation of the 
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molecule, significantly increasing the effectiveness and affinity of the inhibitor for PDE5 [8]. 
In the pharmacokinetic evaluation of this drug, studies reported rapid absorption with a 
tmax approximately 35 minutes and a short t1/2 of less than 1.5 hours without any 
unwanted accumulation of the drug [4]. Favorable data from a nitrate interaction study 
showed only a modest impact on blood pressure and heart rate [23-24].  
2.1.4 Lodenafil 
Lodenafil carbonate is a newer PDE5 inhibitor; it is a dimer formed by two lodenafil 
molecules linked by a carbonate bridge [11]. After ingestion, the carbonate bridge is broken 
delivering the active lodenafil compound [8, 25]. The effects of lodenafil have been 
extensively investigated in vitro; the drug was noted to cause concentration-dependent 
relaxation of both rabbit and human corpus cavernosum tissue by amplifying the NO-
dependent relaxation of the penile tissue in response to acetylcholine or transmural 
electrical field stimulation (EFS) [8]. In comparison lodenafil was shown to be 
approximately twofold more potent than sildenafil for inhibition of the breakdown of cGMP 
[26]. Its efficacy and safety at doses of 20 mg, 40 mg and 80 mg was also tested and shown to 
significantly improve erectile International Index of Erectile Function domain scores (IIEF 
domain scores: a widely used, multi-dimensional self-reporting instrument for the 
evaluation of male sexual function), with only mild to moderate adverse reactions such as 
headache, flushing, visual disorders, and dyspepsia [9, 26]. Lodenafil is an attractive 
pharmacotherapy agent for the treatment of ED [25-26]. 
2.1.5 Tadalafil 
Tadalafil has proven to be efficacious in a number of special populations of men in which 
ED is due to a variety of conditions including diabetes, radiation therapy for prostatic 
cancer, spinal cord injury, and lower urinary tract infection [9, 27]. When taken at doses of 
10 and 20 mg, tadalafil significantly improved erectile function and was well-tolerated, as 
the only reported side effects were headache, flushing, indigestion, nasal congestion, and 
back or girdle pain [9, 27-28]. At present there is no convincing evidence of any significant 
safety issues regarding cardiovascular contraindications with the use of tadalafil when 
taking the recommended doses of 2.5 mg and 5 mg per day [7, 28]. 
2.1.6 Vardenafil 
Vardenafil is an effective vasoactive agent for the treatment of ED in a broad population at 
doses of 10 mg and 20 mg [9, 29]. Vardenafil was even able to cause adequate erections for 
sexual activity in special populations, where ED was a result of diabetes, chemotherapy, 
depression, hypertension, and spinal cord injury [9, 29]. Vardenafil has a mechanism of 
action similar to other PDE5 inhibitors, thus its side effects are similar to those reported by 
other PDE5 inhibitors such as headache, flushing, indigestion, and nasal congestion [4, 9]. 
Overall, vardenafil remains a highly recommended vasoactive agent, since it has been 
proven beneficial for a wide variety of patients with ED, and at present, there is no 
convincing evidence of any significant safety issues, regarding cardiovascular 
contraindications, with its use [7, 9, 29].  
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2.2 Trazodone 
Trazodone is an “atypical” antidepressive agent and it selectively inhibits central 5-
hydroxytryptamine (5-HT) uptake by increasing the turnover of brain dopamines [30]. 
Trazodone has alpha-adrenergic blocking effects (α-AR) and, together with its meta-
chlorophenylpiperazine (m-CCP) metabolite, trazodone is known to induce erections in 
animal studies by selectively blocking the α-AR receptors and by increasing the 
spontaneous firing rate of cavernosal tissue nerves [31]. Despite its promising mode of 
actions within the cavernosum tissue, trazodone is not an effective treatment for most men 
with ED, since orally administered trazodone has been associated with high frequencies of 
priapism [32]. Furthermore, in a double-blind, placebo trial trazodone was not effective even 
at high doses of 150 to 200 mg per day [30, 33-34]. However, trazodone is still a viable option 
for men with psychogenic ED, resulting from anxiety or depression [33-34].  
2.3 Melanocortin receptor agonists (PT-141)  
PT-141 was initially produced as a tanning agent; however it was discovered, when it was 
injected subcutaneously, to initiate potent erections in men with nonorganic ED [35-36]. PT-
141 is a synthetic cyclic nonselective melanocortin receptor agonist, with a high affinity to 
MC receptors 1, 3, and 4, and it is believed to be a metabolite of melanotan-II (MT-II) [36]. 
Theoretically, MC receptor agonists may have beneficial effects in patients with ED based on 
the results from a double-blind, placebo-controlled study in which PT-141, at doses ranging 
from 4 to 20 mg, was administered to 32 healthy subjects [37]. Results from this study 
showed that PT-141 significantly increased erectile activity even without visual sexual 
stimulation, compared with placebo-treated subjects. Additionally, in a placebo-controlled 
crossover trial, men with mild to moderate ED, treated with PT-141 together with visual 
sexual stimulation, experienced a threefold increase in erectile activity when compared to 
the placebo [37]. Co-administration of PT-141 with sildenafil 25 mg significantly increased 
penile rigidity when compared with sildenafil alone [7, 37]. It was also noted that, when 
patients took the two drugs in combination, there were no significant increase in the side 
effects, compared to those experienced, when taking either sildenafil or PT-141 alone [7].  
2.4 Potassium-channel Openers  
Potassium channel openers such as pinacidil, cromakalim, lemakalim, and nicorandil have 
all been shown as efficacious in achieving erections in men with ED [7]. Potassium channel 
openers work by hyperpolarizing the cell membrane, which increases the cell membrane 
permeability to potassium ions causing relaxation and subsequent erection [7]. Presently, 
clinical experience with these potassium channel openers for treatment of ED is limited; 
therefore, potassium channel agonist drugs have not been approved in controlled clinical 
trials as an alternative treatment for men with ED [7].  
2.5 Rho-kinase inhibitors  
Smooth muscle contraction and relaxation is related to the level of free cytosolic calcium, 
which is partly regulated by the accumulation of intracellular secondary messengers such as 
inositol triphosphate (IP3) and diacylglycerol (DAG) via phospholipase C (PLC) activation 
[3]. PLC activation facilitates the release of and the increase of intracellular Ca2+ 
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concentration, resulting in calcium binding to calmodulin and subsequent activation of 
myosin light chain kinase [3]. When intracellular calcium levels decrease, RhoA, a small 
monomeric G protein, activates Rho-kinase; in turn, Rho-kinase phosphorylates and 
simultaneously inhibits the regulatory subunit of myosin light chain phosphatase [3, 38-39]. 
Thus, Rho-kinase is considered essential to the cell calcium sensitization system as its 
activation creates a cascade whereby the phosphorylation of myosin light chains triggers 
cycling of myosin cross-bridges along actin filaments, generating a contractile force that is 
maintained, unless inhibited, within the corpus cavernosum tissue [38]. It was first shown 
by Chitaley, K., et al. that Rho-kinase contributes to smooth muscle tone in the corpus 
cavernosum [40]. Injection of the Rho-kinase inhibitor Y-27632 into cavernosal sinuses 
increased intracavernosal pressure within minutes in a dose-dependent manner, without 
significantly decreasing systemic blood pressure [40]. Furthermore, the increase in 
intracavernosal pressure with Rho-inhibition was independent of the relaxing effects of N.O. 
and of guanylate cyclase, indicating that the Rho-kinase pathway may be an alternative 
therapeutic target for treating ED [38, 40]. In animal studies the Rho-kinase inhibitor fasudil, 
was effective against vasculogenic ED, in addition it was capable of reducing levels of pelvic 
atherosclerosis [41]. In a recent study involving diabetic-associated ED in rats, it was shown 
that chronic administration of fasudil was more effective, than other popular ED treatments, 
at reversing the damaging biochemical changes invoked by high insulin levels [42]. 
Human clinical trials have recently reported that low-dose atorvastatin (Lipitor), (a drug 
which works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue, that plays 
a key role in production of cholesterol in the body), normalizes the diabetic response to 
sildenafil in streptozotocin (STZ) treated diabetic rats [43]. This result suggests that statins 
may also have inhibitory actions in the RhoA/Rho-kinase mechanism [42-43].  
2.6 Alternative treatments for ED 
2.6.1 HERBAL treatment for ED (Yohimbine)  
Though herbal medicines are not a prescribed option of choice for patients in the United 
States, in other parts of the world like Asia, Africa and the Middle East, it is a widely used 
form of therapy for men with ED [44]. However, although there are a myriad of herbal 
treatments that are very appealing for patients with ED, caution must be warranted, since 
some herbal medicines may cause deleterious drug interactions, especially in men with 
comorbid diseases such as CV and diabetes. On the other hand, the herbal or traditional 
therapeutic approach may be more culturally acceptable with some patients, who may 
prefer this holistic option because of religious, social, monetary or other personal 
preferences. As a result, there is a growing interest among the population for alternative 
holistic treatment options, which has increased demand for such therapies in the United 
States [44]. Though there are many herbal remedies available at present for ED, this review 
will focus on the efficacy of yohimbine.   
Yohimbine is an alkaloid derived from the African yohimbe tree (Pausinystalia yohimbe) [44]. 
Yohimbine has been well characterized as an alpha-2 adrenergic receptor (α2-AR) antagonist 
[44]. It specifically inhibits the pre-synaptic α-2 adrenergic receptors in the brain; as a result 
there is a reduction of sympathetic tone since the brain and spinal cord noradrenaline levels 
are diminished [45]. The plasma half-life of yohimbine was found to be 0.6 hours, whereas 
www.intechopen.com
 
Current Perspectives on Pharmacotherapy Treatments for Erectile Dysfunction 
 
151 
the plasma noradrenergic effects of the drug lasted for more than 12 hours [46]. 
Theoretically, yohimbine should be a very effective treatment for ED; nevertheless, in 
several controlled trials on patients with different types of ED, yohimbine only produced 
modest effects [7]. However, a comprehensive systematic review demonstrated the 
advantage of yohimbine over a placebo in the treatment of ED [44, 47]. In combination with 
other drugs, oral yohimbine (15 mg daily) with trazodone (50 mg daily) was found to be a 
safe and effective treatment for psychogenic ED [44]. Despite its growing popularity, 
yohimbine is not currently recommended in most guidelines for management of ED, due to 
conflicting  clinical reports concerning its efficacy [7].        
2.6.2 Antioxidant therapy (Quercetin) 
Oxidative stress occurs when there is an imbalance between pro-oxidants and antioxidants’ 
ability to scavenge reactive oxygen species (ROS) [48]. ROS rapidly inactivate NO, thereby 
limiting its ability to relax smooth muscle [49]. Studies have also demonstrated that ROS 
have a central role in inducing apoptosis in cavernosum tissues [49-50]. Thus, there is 
overwhelming evidence implicating the role of oxidative stress in the pathophysiology of 
ED [48]. As a result, antioxidant treatment to regulate ROS is being explored as a potential 
therapeutic treatment for ED [49].  
Quercetin (pentahydroxyflavone) is the most abundant flavonoid in the human diet, and it 
is available without a prescription as a dietary supplement [51]. Flavonoids are plant phenolic 
compounds with strong antioxidant properties, and they are found in various dietary sources, 
such as tea, onion, and broccoli. Quercetin is a potent anti-oxidant, and its mechanism of action 
involves the direct scavenging of free radicals such as hydrogen peroxide and superoxide, the 
inhibition of the pro-oxidant enzyme xanthine oxidase, the inhibition of lipid peroxidation, the 
chelating of iron and the altering of the anti-oxidant defense pathways in the cell [51-52]. 
Given its beneficial effects against oxidative damage, quercetin was hypothesized to be 
effective in the treatment of ED, in particular ED as a result of diabetes mellitus [51-52]. Animal 
studies have revealed that quercetin treatment effectively improved intracavernosal pressure 
of diabetic rats by preserving superoxide dismutase (SOD) activity, (an antioxidant enzyme), 
while simultaneously increasing endothelial nitric oxide synthase (eNOS) expression. The 
results clearly demonstrate that eNOS expression and NO levels in corpus cavernosum were 
significantly increased in diabetic rats, in response to quercetin treatment [52]. Though these 
studies show a promising potential for quercetin, more investigations are needed to establish 
its efficacy in human penile tissue.   
3. Second-line treatment: Intracavernosal pharmacotherapy 
Intracavernosal injection (ICI) is a second-line therapy that is mainly considered for patients 
who fail to respond to first-line therapy or those who cannot use the least invasive forms of 
currently available pharmacotherapy [53]. The ideal candidates for ICI therapy are those 
who use nitrates or could potentially use nitrates, have neural injury from pelvic surgery, 
trauma, diabetic patients, and patients who desire rapid onset of erection, greater rigidity 
and or duration of erection [54]. Contraindications for ICI therapy include patients with a 
history of priapism with vasoactive drug use, and those with severe penile fibrosis with the 
use of monoamine oxidase inhibitors (MAOIs); in addition, a nonresponse to ICI occurs 
mostly as a result of an inadequate dose, misdirected injection into the subcutaneous or  
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Fig. 1. SOD in the Pathophysiology of Erectile Dysfunction: During oxidative stress, SOD 
expression decreases causing an increase in superoxide (O2-). As O2- rises within the cell, NO 
production is attenuated leading to ED. 
trabecular regions of the penis, leakage of vasoactive agent prior to ICI and insufficient 
sexual stimulation, or premature ejaculation [54]. 
Following an ICI and sexual stimulation, penile rigidity is achieved usually within 5–10 
minutes, as a rapid increase in cavernosal artery blood flow leads to compression of 
subtunical venules located between the smooth muscle of the corpora cavernosa and the inner 
tunica albuginea (3). With venous outflow blocked, intracavernosal pressures can be greater 
than 100 mmHg. Vasoconstriction and the loss of penile rigidity occur as a result of an 
increase in sympathetic tone coincident with ejaculation (3). For ICI therapy, the most 
commonly prescribed vasoactive agents are prostaglandin E-1 (PGE-1), phentolamine, and 
papaverine (1, 3). However, with advances in medical research, other effective treatments 
are currently available, such as vasoactive intestinal polypeptide, calcitonin gene-related 
peptide, and guanylate cyclase activators.  
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3.1 Papaverine  
Papaverine was discovered by Merck in 1848, it is an opium alkaloid originating from the 
poppy Papaver somniferum. In the treatment of ED, intracavernosal papaverine injection was 
the first pharmacological agent proven to be a clinically effective therapy for ED (1). 
Papaverine induces relaxation of the corpus cavernosal smooth muscle tissue and pudendal 
artery leading to penile erection via nonspecific inhibition of phosphodiesterase, leading to 
increased intracellular levels of cGMP and cyclic adenosine monophosphate (cAMP) (1). In 
in vitro studies, papaverine was shown to increase relaxation not only in isolated corpus 
cavernosum smooth muscle strips, but also in penile arteries and penile veins; in addition, 
these studies have also shown that papaverine was able to attenuate contractions induced 
by stimulation of adrenergic nerves and exogenous noradrenaline [9]. Papaverine may also 
regulate corpus cavernosum smooth muscle tone via a cAMP independent pathway by the 
inhibition of voltage-dependent L-type calcium channels [9, 55]. 
Although papaverine is an effective and inexpensive treatment for ED, compiled reports 
have implicated the use of papaverine with an increased rate of priapism and fibrosis [20, 
56-57]. Penile pain is also very common following administration of papaverine [57-58]. 
Papaverine may cause other side effects such as flushing, sweating, upset stomach, loss of 
appetite, diarrhea, constipation, and irregular heartbeat [9, 59]  
3.2 Alpha-adrenoreceptor antagonist (Phentolamine) 
Although the beneficial vasoactive effects of phentolamine were discovered in the 1970s, the 
current clinical use of this drug is limited to use as a component of other vasoactive drug 
combinations [20, 60]. In the penile corpus cavernosum, there are at least three important 
alpha-adrenoreceptor iso-forms: 1A, 1B, and 1D. All three subtypes have been detected 
and the 1A and 1D proteins have been identified as the predominant subtypes in the 
corpus cavernosa [61-62]. However, the distinction and role of each individual receptor 
subtype to cell signaling pathways in erectile function remains mostly undetermined [63]. 
Alpha-1 and 2-adrenoreceptors are classified as G-protein coupled receptors which initiate 
several complex downstream processes [61]. It has been suggested that alpha 1 receptors 
preserve the penile contractile tone by increasing intracellular calcium levels followed by 
extracellular calcium influx [61]. It should also be noted that the -adrenergic receptor 
system plays a critical role in the modulation of penile flaccidity (8). Contraction induced by 
post-junctional 2-receptors is caused by increased intracellular calcium but also involves 
the recruitment of ion channels, activation of phosphodiesterases and attenuation of 
adenylate cyclase activity [60, 64]. 
Phentolamine mesylate produces an -adrenergic blockade; it is a nonselective -
adrenoreceptor antagonist with a similar affinity for 1 and 2-adrenoreceptors; it also has 
direct, positive inotropic and chronotropic effects on cardiac muscle, as well as vasodilator 
effects on vascular smooth muscle [20]. Although ICI of phentolamine increases corporal 
blood flow, a concurrent increase in noradrenaline prevents sinusoidal relaxation [65]. 
Studies have also shown that phentolamine induces the relaxation of corpus cavernosum 
erectile tissue independently of 1 and 2-adrenoreceptors blockades, via a noradrenergic, 
endothelium-mediated mechanism suggesting NO synthase activation (68, 77).  
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3.3 Prostaglandin E1  
Prostaglandins were first characterized by Bergstrom, S., Bengt, S. and Vane, J. however, it 
was not until 1986 that the vasoactive effects of prostaglandin E1s (PGE-1) were described 
for intracavernosal use by Ishii, N. and Adaikan, PG. [20]. In 1996, PGE-1 became the first 
FDA-approved vasoactive intracavernosal drug for the treatment of ED, and its efficacy has 
been confirmed in three multi-centered, randomized prospective clinical trials with a six-
month open-label extension [66]. Since then, a vast body of knowledge has described the 
efficacy and mechanism of this drug. Presently, PGE-1 is one of the most popular vasoactive 
agents for ICI therapy [67]. 
PGE-1 induces relaxation of human corpus cavernosum smooth muscle by regulating 
adenylate cyclase activity, upregulating the production of cAMP in the penis via activation 
of EP prostaglandin receptors, and subsequently leading to a decrease in intracellular 
calcium concentration, resulting in cavernosal smooth muscle relaxation [9, 20, 68-69]. PGE-
1 mediated vaso-dilation occurs via gap junctions within the penis; additionally PGE-1 
inhibits sympathetic activity by acting upon the presynaptic neurons, blocking the release of 
noradrenaline [70-72]. PGE-1 is metabolized by 15-hydroxydehydrogenase and has a blood 
plasma half-life of less than 1 minute, as liver, kidney, and penile enzymes all contribute to 
the conversion of PGE-1 to its inactive form [67]. Rates of priapism, a potentially devastating 
adverse effect, are low with the use of PGE-1, which makes it the most utilized injectable 
vasoactive agent [20]. 
3.4 Vasoactive Intestinal Polypeptide 
Vasoactive intestinal peptide (VIP) is a naturally occurring neurotransmitter and a potent 
smooth muscle relaxing agent. VIP, which was isolated from the small intestine, was also 
first described as a specific neurotransmitter for inducing penile erection in 1986 [73]. While 
VIPergic nerves are most densely concentrated in the penis around the pudendal arteries, 
preliminary intracavernosal studies using VIP produced unsatisfactory results; however, 
when VIPs were used in combination with drugs such as papaverine and phentolamine, 
adequate penile erections were observed [9, 74]. As a result, current VIP therapy for ED is 
predominantly used in combination with phentolamine mesylate [20]. 
The effects of VIP are mediated via a specific G protein-coupled receptor (GPCR) which is 
linked to adenylate cyclase [9]. VIP co-localizes with nitric oxide synthase (NOS) within the 
perivascular and trabecular nerve fibers innervating the penis, thus regulating penile blood 
flow, and smooth muscle tone in the male genitalia [75]. Most of the NO and VIPergic 
nerves are cholinergic in nature, as they contain a vesicular acetylcholine transporter [76]. 
Given that the actions of VIP have been directly linked to adenylate cyclase, VIP can elevate 
cAMP concentrations in cavernosal tissues without affecting cGMP levels [77]. VIP has 
commonly observed side effects, such as facial flushing and headaches, which are frequent 
events characteristic of most vasoactive therapies [78]. 
3.5 Linsidomine chlorhydrate 
Nitric oxide donors such as sodium nitroprusside (SNP) and linsidomine (SIN-1) can be 
used for the treatment of ED [79]. In vivo studies have shown that SNP and linsidomine 
(SIN-1) upregulates cGMP production, which increases NO release in a dose-dependent 
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manner [80]. NO release causes the relaxation of vascular smooth muscle as well as 
cavernosum smooth muscle. Even though SIN-1 has a short half-life of only 1–2 min, there is 
a potential to cause systemic hypotension with use of this drug [81-82]. SNP and SIN-1 have 
positive hemodynamic effects promoting erectile function and show long-term promise as 
intracavernosal vasoactive agents compared to other forms of intracavernosal treatment 
[83]. 
 
 
Fig. 2. Pharmacotherapy treatments for ED: Cavernosal nerves contribute to smooth muscle 
relaxation by releasing Acetylcholine (Ach). Trazadone increases cavernosal nerve firing, 
which increases Ach release, which stimulates eNOS, causing the release of NO. ROS causes 
eNOS uncoupling, which reduces its activity, however Quercetin has potent antioxidant 
effects and effectively reduces ROS generation. Once NO is released, it activates sGC, 
increasing the cGMP levels. SIN-1 and PDE5 inhibitors, such as sildenafil, also elevates 
cGMP levels resulting in the activation of PKG. On the other hand, PGE-1 and Papaverine 
elevates cAMP, causing the activation of PKA. PKG and PKA activation causes a cell 
signaling cascade which hyperpolarizes the cell membrane. Nicorandil also has similar 
hyperpolarizing effects by opening the potassium channels. Overall activation of PKG and 
PKA reduces intracellular calcium levels, resulting in increased activity of myosin-light 
chain phosphatase resulting in smooth muscle relaxation and subsequent erection. Fasudil 
also increases myosin-light chain phosphatase leading to smooth muscle relaxation by 
inhibition of Rho-kinase. Erections are also caused by neural stimulation, through the 
release of neuronal NO.  
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3.6 Calcitonin Gene-Related Peptide 
Calcitonin-gene-related peptide (CGRP) causes an increase in penile arterial inflow, 
cavernosal smooth muscle relaxation and cavernosal outflow occlusion [84]. As a potent 
vasodilator, CGRP has also been shown to induce dose-related increases in penile blood 
flow with CGRP-specific receptor agonists [84-85]. For the treatment of ED, CGRP is usually 
co-administered with PGE-1, and this combined therapy has been proven successful in 
improving erectile function [86]. 
3.7 Guanylate Cyclase activator 
Soluble guanylate cyclase (sGC) activators have been shown to increase intracavernosal 
pressure in corpus cavernosum tissue (23-24). BAY41-2272 is a sGC activator that has been 
shown to relax the human corpus cavernosum with or without the presence of NO (16). The 
sGC enzyme converts GTP to cGMP, which is activated when NO is released from erectile-
autonomic nerves, resulting in smooth muscle relaxation. In the penis, cGMP is a down-
stream cell-signal messenger that relaxes cavernosal smooth muscle, causing adequate blood 
flow for penile erection (23).  
4. Conclusion 
ED will continue to be a problem affecting many individuals. Though there are advances in 
the treatment of ED, there is still a need for more effective therapy for men with complex ED 
caused by comorbid diseases such as diabetes. In addition, there are an increasing number 
of patients with cardiovascular disease for whom first-line and second-line 
pharmacotherapy are contra-indicated. For first-line therapy, the major drawback is severe 
hypotension and bothersome side effects including headaches, dizziness, vision and hearing 
changes, which sometimes occur during sexual activity. For second-line therapy, even 
though it is an effective alternative for men who cannot tolerate or respond to first-line 
therapy, the chief drawback of such an approach is a high attrition rate. However, although 
this chapter did not focus on the option of combination therapy, (the combined used of 
various oral vasoactive drugs and or intracavernosal therapies), this form of therapy is 
becoming an increasingly popular option for patients and may represent the most 
promising alternative for men with complex ED. At present it is very common, especially for 
second-line ED treatment algorithms to include combination therapy. Therefore, as we 
move ahead into the future, we can better understand and provide more appealing options 
for the management of ED, through continued combined efforts of researchers and 
clinicians.  
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